Trial Profile
A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary) ; Bortezomib; Romidepsin
- Indications Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Adverse reactions
- 23 Feb 2022 Planned End Date changed from 1 May 2022 to 1 May 2024.
- 23 Feb 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2024.
- 23 Feb 2022 Status changed from recruiting to active, no longer recruiting.